![](/img/cover-not-exists.png)
Lurbinectedin (PM01183) administered once (D1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer
Sauri, T., Awada, A., Calvo, E., Moreno, V., Szyldergemajn, S., Elez, E., Barthelemy, P., Boni, V., Doger, B., Teruel, C. Fernandez, Soto-Matos, A., Tabernero, J., Aftimos, P.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw368.35
Date:
October, 2016
File:
PDF, 39 KB
english, 2016